Sichuan Biokin Pharmaceutical Co. Ltd. A
Sichuan Biokin Pharmaceutical Co.,Ltd. engages in the research and development, production, and supply of biomedicine in the fields of antibody drug conjugate, guidance navigation and control, and antibody radionuclide conjugate in China and internationally. It offers anesthesia, parenteral nutrition, anti-infectives, pediatrics, and traditional Chinese medicines. The company was founded in 1996 … Read more
Sichuan Biokin Pharmaceutical Co. Ltd. A (688506) - Total Liabilities
Latest total liabilities as of June 2025: CN¥4.39 Billion CNY
Based on the latest financial reports, Sichuan Biokin Pharmaceutical Co. Ltd. A (688506) has total liabilities worth CN¥4.39 Billion CNY as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Sichuan Biokin Pharmaceutical Co. Ltd. A - Total Liabilities Trend (2021–2024)
This chart illustrates how Sichuan Biokin Pharmaceutical Co. Ltd. A's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Sichuan Biokin Pharmaceutical Co. Ltd. A Competitors by Total Liabilities
The table below lists competitors of Sichuan Biokin Pharmaceutical Co. Ltd. A ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Cngr Advanced Material Co Ltd
SHE:300919
|
China | CN¥46.91 Billion |
|
Atco Ltd
PINK:ACLLF
|
USA | $18.25 Billion |
|
Ansell Limited
PINK:ANSLF
|
USA | $1.34 Billion |
|
Dr. Ing. h.c. F. Porsche AG
PINK:DRPRF
|
USA | $30.90 Billion |
|
Metaplanet Inc.
PINK:MTPLF
|
USA | $17.84 Billion |
|
Fortress Transportation and Preferred Series B
NASDAQ:FTAIO
|
USA | $3.96 Billion |
|
Shift4 Payments Inc 6% PRF CONVERT 01/05/2028 USD 100 - Ser A
NYSE:FOUR-PA
|
USA | $6.76 Billion |
|
Curbline Properties Corp.
NYSE:CURB
|
USA | $556.32 Million |
Liability Composition Analysis (2021–2024)
This chart breaks down Sichuan Biokin Pharmaceutical Co. Ltd. A's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.66 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.57 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.61 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Sichuan Biokin Pharmaceutical Co. Ltd. A's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Sichuan Biokin Pharmaceutical Co. Ltd. A (2021–2024)
The table below shows the annual total liabilities of Sichuan Biokin Pharmaceutical Co. Ltd. A from 2021 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥3.25 Billion | +155.37% |
| 2023-12-31 | CN¥1.27 Billion | +20.40% |
| 2022-12-31 | CN¥1.06 Billion | +70.68% |
| 2021-12-31 | CN¥619.61 Million | -- |